Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies
Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, Andrea Antinori, Roberto Ortiz, Amanda Clarke, Chien‐Ching Hung, JK Rockstroh, PM Girard, Jörg Sievers, C Man, Rimgaile Urbaityte, Mark Underwood, A. Tenorio, Keith A. Pappa, Brian Wynne, Martin Gartland, Michael Aboud, Jean van Wyk, K. Smith, Y. El-Bahy
Topics & Concepts
DolutegravirLamivudineMedicineHuman immunodeficiency virus (HIV)Antiretroviral treatmentVirologyAntiretroviral therapyPharmacologyViral loadChronic hepatitisVirusHIV/AIDS drug development and treatmentHIV-related health complications and treatmentsHIV/AIDS Research and Interventions